Genmab’s latest phase 2 data spur claim ADC is ‘clearly superior’ to AbbVie’s Elahere
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Genmab’s latest phase 2 data spur claim ADC is ‘clearly superior’ to AbbVie’s Elahere" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Endpoints News, TradingView, The Pharma Letter and Business Wire. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 1h ago.
Quick answers
Why is "Genmab’s latest phase 2 data spur claim ADC is ‘clearly superior’ to AbbVie’s El" trending?
Because 5 independent news sources published 5 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (6)
- Genmab’s Phase 2 data strengthens case for $1.8B ProfoundBio bet European Biotechnology Magazine · 13h ago
- Genmab details ovarian cancer data; Lilly’s Jaypirca gets a label expansion Endpoints News · 13h ago
- Weekly Recap: Rina‑S 45.9% ORR and Darwin Global 5.11% voting control TradingView · 13h ago
- Genmab’s Rina-S shows durable responses in ovarian cancer The Pharma Letter · 13h ago
- Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer Business Wire · 13h ago
- Genmab’s latest phase 2 data spur claim ADC is ‘clearly superior’ to AbbVie’s Elahere Fierce Biotech · 13h ago
Topics
Related trends
AbbVie's Cerevel buyout delivers as FDA gives go-ahead to 1st-in-class Juvmo in Parkinson's disease
The FDA has approved Juvmo, a first-in-class Parkinson's disease medication, validating AbbVie's $8.7 billion acquisition of Cerevel.
Merck, Daiichi pull lung cancer filing after FDA pushback deals another blow to $4B deal
Merck and Daiichi Sankyo pull their US lung cancer drug application following regulatory pushback.
New Parkinson’s drug approved in the US: What does it do differently?
The U.S. FDA has approved AbbVie's Juvmo, a first-in-class medication designed to provide a next-generation treatment option for Parkinson's disease.
Modular in vivo antibody–ADC click to reverse drug resistance in tumours
A new modular in vivo antibody-ADC click chemistry approach aims to reverse drug resistance in tumors, including pancreatic cancer.
EXCLUSIVE: US House committee opens investigation into Merck, AbbVie China drug trials
A US House committee has launched an investigation into major pharmaceutical companies regarding the use of clinical trial sites in China.
Lilly, J&J and AbbVie Hit New Highs
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.